In vitro antimicrobial resistance in clinical isolates of bacterial pathogens causing bovine respiratory disease: a systematic review and meta-analysis
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Background
Bovine respiratory disease (BRD) is a major cause of antimicrobial use in cattle, raising concerns about antimicrobial resistance (AMR). This systematic review estimated pooled AMR proportions in BRD pathogens: Mannheimia haemolytica, Pasteurella multocida , and Histophilus somni , and assessed temporal and geographic trends in resistance.
Methods
Five antimicrobials commonly used for BRD treatment were evaluated: penicillin G (PEN), tetracycline (TET), florfenicol (FLO), tulathromycin (TUL), and enrofloxacin (ENR). Following PRISMA guidelines, 1,097 records were screened and 24 studies met inclusion criteria. Study quality and risk of bias were assessed, and random-effects meta-analyses estimated pooled proportions of resistant isolates by antimicrobial, continent and period.
Results
A total of 13,949 bacterial isolates were analysed including P. multocida (5,615), M. haemolytica (5,585), and H. somni (2,749). TET resistance was highest across all pathogens (12-30%), followed by TUL (6-11%), PEN (4-12%), FLO (0.5-1.6%) and ENR (0.2-1.1%). TET resistance in M. haemolytica and P. multocida , and FLO resistance in P. multocida were significantly more frequent in North America than in Europe ( p ≤0.05). TUL resistance increased significantly in P. multocida after 2013 ( p =0.038), with similar non-significant trends in M. haemolytica and H. somni . FLO resistance decreased significantly in H. somni after 2013 (p=0.013). Egger’s test identified significant funnel-plot asymmetry for ENR resistance in H. somni and PEN resistance in M. haemolytica , suggesting possible small-study effects.
Conclusion
These results offer insights into distribution of phenotypic resistance across pathogens and regions, informing BRD antimicrobial treatment guidelines and One-Health antimicrobial stewardship aimed at preserving the effectiveness of medically important antimicrobials.
